Skip to main content

Articles

Page 1 of 66

  1. Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in ovarian carcinoma (OC). While the role of DOT1L in cancer and chemoresistance is acknowledged, its specific role in PA...

    Authors: Chaohua Liu, Jiana Li, Fei Xu, Lihua Chen, Mengdong Ni, Jiangchun Wu, Haiyun Zhao, Yangjun Wu, Jiajia Li, Xiaohua Wu and Xiaojun Chen
    Citation: Molecular Cancer 2024 23:111
  2. Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor...

    Authors: Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang and Jiong Chen
    Citation: Molecular Cancer 2024 23:109
  3. Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein...

    Authors: Xin Lin, Kuan Kang, Pan Chen, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Mei Yi and Bo Xiang
    Citation: Molecular Cancer 2024 23:108
  4. Neutrophils play a Janus-faced role in the complex landscape of cancer pathogenesis and immunotherapy. As immune defense cells, neutrophils release toxic substances, including reactive oxygen species and matri...

    Authors: Xueqin Huang, Eugenie Nepovimova, Vojtech Adam, Ladislav Sivak, Zbynek Heger, Marian Valko, Qinghua Wu and Kamil Kuca
    Citation: Molecular Cancer 2024 23:107
  5. Aging and cancer exhibit apparent links that we will examine in this review. The null hypothesis that aging and cancer coincide because both are driven by time, irrespective of the precise causes, can be confr...

    Authors: Léa Montégut, Carlos López-Otín and Guido Kroemer
    Citation: Molecular Cancer 2024 23:106
  6. The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess...

    Authors: Luca Ponzone, Valentina Audrito, Claudia Landi, Enrico Moiso, Chiara Levra Levron, Sara Ferrua, Aurora Savino, Nicoletta Vitale, Massimiliano Gasparrini, Lidia Avalle, Lorenza Vantaggiato, Enxhi Shaba, Beatrice Tassone, Stefania Saoncella, Francesca Orso, Daniele Viavattene…
    Citation: Molecular Cancer 2024 23:105
  7. The faithful maintenance of DNA methylation homeostasis indispensably requires DNA methyltransferase 1 (DNMT1) in cancer progression. We previously identified DNMT1 as a potential candidate target for oral squ...

    Authors: Yangfan Liu, Yu Sun, Jin Yang, Deyang Wu, Shuang Yu, Junjiang Liu, Tao Hu, Jingjing Luo and Hongmei Zhou
    Citation: Molecular Cancer 2024 23:104
  8. Pancreatic ductal adenocarcinoma (PDAC) is marked by a dismal survival rate, lacking effective therapeutics due to its aggressive growth, late-stage diagnosis, and chemotherapy resistance. Despite debates on N...

    Authors: Miltiadis Tsesmelis, Ulrike F. G. Büttner, Melanie Gerstenlauer, Uta Manfras, Konstantinos Tsesmelis, Ziwei Du, Nadine Sperb, Stephanie Ellen Weissinger, Peter Möller, Thomas F. E. Barth, Harald J. Maier, Lap Kwan Chan and Thomas Wirth
    Citation: Molecular Cancer 2024 23:103
  9. Peptides and proteins encoded by noncanonical open reading frames (ORFs) of circRNAs have recently been recognized to play important roles in disease progression, but the biological functions and mechanisms of...

    Authors: Yaming Li, Zekun Wang, Jingwen Yang, Yuhan Sun, Yinqiao He, Yuping Wang, Xi Chen, Yiran Liang, Ning Zhang, Xiaolong Wang, Wenjing Zhao, Guohong Hu and Qifeng Yang
    Citation: Molecular Cancer 2024 23:102
  10. Long noncoding RNAs (lncRNAs) have surpassed the number of protein-coding genes, yet the majority have no known function. We previously discovered 844 lncRNAs that were genetically linked to breast cancer thro...

    Authors: Lu Wang, Mainá Bitar, Xue Lu, Sebastien Jacquelin, Sneha Nair, Haran Sivakumaran, Kristine M. Hillman, Susanne Kaufmann, Rebekah Ziegman, Francesco Casciello, Harsha Gowda, Joseph Rosenbluh, Stacey L. Edwards and Juliet D. French
    Citation: Molecular Cancer 2024 23:101
  11. Authors: Xiangyu Jian, Han He, Jiehong Zhu, Qi Zhang, Zhongxin Zheng, Xiangjing Liang, Liuyan Chen, Meiling Yang, Kaiyue Peng, Zhaowen Zhang, Tengfei Liu, Yaping Ye, Hongli Jiao, Shuyang Wang, Weijie Zhou, Yanqing Ding…
    Citation: Molecular Cancer 2024 23:100

    The original article was published in Molecular Cancer 2020 19:20

  12. The gut microbiota has been demonstrated to be correlated with the clinical phenotypes of diseases, including cancers. However, there are few studies on clinical subtyping based on the gut microbiota, especial...

    Authors: Wenxing Qin, Jia Li, Na Gao, Xiuyan Kong, Liting Guo, Yang Chen, Liang Huang, Xiaobing Chen and Feng Qi
    Citation: Molecular Cancer 2024 23:99
  13. DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeuti...

    Authors: Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li and Kai He
    Citation: Molecular Cancer 2024 23:97
  14. Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality of life for cancer patients. We devel...

    Authors: Pinli Yue, Fenglong Bie, Jiarun Zhu, Lin-Rui Gao, Zhendiao Zhou, Guangyu Bai, Xiaobing Wang, Ziyi Zhao, Ze-Fen Xiao, Yong Li, Aiping Zhou, Wen-Yang Liu, Yuchen Jiao and Shugeng Gao
    Citation: Molecular Cancer 2024 23:96
  15. Active targeting by surface-modified nanoplatforms enables a more precise and elevated accumulation of nanoparticles within the tumor, thereby enhancing drug delivery and efficacy for a successful cancer treat...

    Authors: José L. Blaya-Cánovas, Carmen Griñán-Lisón, Isabel Blancas, Juan A. Marchal, César Ramírez-Tortosa, Araceli López-Tejada, Karim Benabdellah, Marina Cortijo-Gutiérrez, M. Victoria Cano-Cortés, Pablo Graván, Saúl A. Navarro-Marchal, Jaime Gómez-Morales, Violeta Delgado-Almenta, Jesús Calahorra, María Agudo-Lera, Amaia Sagarzazu…
    Citation: Molecular Cancer 2024 23:83
  16. Dysregulation of immune surveillance is tightly linked to the development of metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC); however, its underlying mechanisms re...

    Authors: Ying Xie, Yu Huang, Zhi-Yong Li, Weihua Jiang, Nan-Xi Shi, Yuanzhi Lu, Guangchao Cao, Zhinan Yin and Xue-Jia Lin
    Citation: Molecular Cancer 2024 23:95
  17. The hypoxic tumor microenvironment is a key factor that promotes metabolic reprogramming and vascular mimicry (VM) in ovarian cancer (OC) patients. ESM1, a secreted protein, plays an important role in promotin...

    Authors: Juan Zhang, Fan Ouyang, Anbo Gao, Tian Zeng, Ming Li, Hui Li, Wenchao Zhou, Qing Gao, Xing Tang, Qunfeng Zhang, Xiaomin Ran, Gang Tian, Xiyun Quan, Zhenzi Tang, Juan Zou, Yifei Zeng…
    Citation: Molecular Cancer 2024 23:94
  18. Circulating tumor cells (CTCs) hold immense promise for unraveling tumor heterogeneity and understanding treatment resistance. However, conventional methods, especially in cancers like non-small cell lung canc...

    Authors: Lisa-Marie Rieckmann, Michael Spohn, Lisa Ruff, David Agorku, Lisa Becker, Alina Borchers, Jenny Krause, Roisin O’Reilly, Jurek Hille, Janna-Lisa Velthaus-Rusik, Niklas Beumer, Armin Günther, Lena Willnow, Charles D. Imbusch, Peter Iglauer, Ronald Simon…
    Citation: Molecular Cancer 2024 23:93
  19. Breast cancer, the most frequent female malignancy, is often curable when detected at an early stage. The treatment of metastatic breast cancer is more challenging and may be unresponsive to conventional thera...

    Authors: Moumita Kundu, Ramesh Butti, Venketesh K. Panda, Diksha Malhotra, Sumit Das, Tandrima Mitra, Prachi Kapse, Suresh W. Gosavi and Gopal C. Kundu
    Citation: Molecular Cancer 2024 23:92
  20. Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence and development of a variety of tumors. The aim of this study was to investiga...

    Authors: Yi-fang Tang, Zheng-hua Liu, Lei-yi Zhang, Sheng-hao Shi, Shun Xu, Jin-An Ma, Chun-Hong Hu and Fang-wen Zou
    Citation: Molecular Cancer 2024 23:91
  21. Metabolic reprogramming and epigenetic alterations contribute to the aggressiveness of pancreatic ductal adenocarcinoma (PDAC). Lactate-dependent histone modification is a new type of histone mark, which links...

    Authors: Fei Li, Wenzhe Si, Li Xia, Deshan Yin, Tianjiao Wei, Ming Tao, Xiaona Cui, Jin Yang, Tianpei Hong and Rui Wei
    Citation: Molecular Cancer 2024 23:90
  22. Ferroptosis is a type of regulated cell death characterized by iron accumulation and uncontrolled lipid peroxidation, leading to plasma membrane rupture and intracellular content release. Originally investigat...

    Authors: Jiandong Diao, Yuanyuan Jia, Enyong Dai, Jiao Liu, Rui Kang, Daolin Tang, Leng Han, Yingjie Zhong and Lingjun Meng
    Citation: Molecular Cancer 2024 23:89
  23. Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating ...

    Authors: Hongli Gao, Zhuo Xi, Jingwei Dai, Jinqi Xue, Xin Guan, Liang Zhao, Zhiguang Chen and Fei Xing
    Citation: Molecular Cancer 2024 23:88
  24. Intratumoral heterogeneity (ITH) and tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) play important roles in tumor evolution and patient outcomes. However, the precise characterization ...

    Authors: Joo Kyung Park, Hyoung-oh Jeong, Hyemin Kim, Jin Ho Choi, Eun Mi Lee, Seunghoon Kim, Jinho Jang, David Whee-Young Choi, Se-Hoon Lee, Kyoung Mee Kim, Kee-Taek Jang, Kwang Hyuck Lee, Kyu Taek Lee, Min Woo Lee, Jong Kyun Lee and Semin Lee
    Citation: Molecular Cancer 2024 23:87
  25. CDC6 is an oncogenic protein whose expression level fluctuates during the cell cycle. Although several E3 ubiquitin ligases responsible for the ubiquitin-mediated proteolysis of CDC6 have been identified, the ...

    Authors: Jianfeng Cui, Xiaochen Liu, Qinghong Shang, Shuna Sun, Shouzhen Chen, Jianping Dong, Yaofeng Zhu, Lei Liu, Yangyang Xia, Yong Wang, Lu Xiang, Bowen Fan, Jiafeng Zhan, Yadi Zhou, Pengxiang Chen, Renchang Zhao…
    Citation: Molecular Cancer 2024 23:86
  26. Nuclear condensates have been shown to regulate cell fate control, but its role in oncogenic transformation remains largely unknown. Here we show acquisition of oncogenic potential by nuclear condensate remode...

    Authors: Junqi Kuang, Pengli Li, Ziwei Zhai, Yixin Fan, HuaiYuan Xu, Chengchen Zhao, Wei Li, Xiaoxi Li, Zechuan Liang, Tao Huang, Yue Qin, Huiru Gao, Zhaoyi Ma, Dong Liu, Guifa Zhong, Bo Wang…
    Citation: Molecular Cancer 2024 23:85
  27. The cell cycle is a crucial biological process that is involved in cell growth, development, and reproduction. It can be divided into G1, S, G2, and M phases, and each period is closely regulated to ensure the...

    Authors: Yuqin Xu, Yue Jiao, Chengbin Liu, Rui Miao, Chunyan Liu, Yilong Wang, Chunming Ma and Jiao Liu
    Citation: Molecular Cancer 2024 23:84
  28. Triple-negative breast cancer (TNBC) stands as the breast cancer subtype with the highest recurrence and mortality rates, with the lungs being the common site of metastasis. The pulmonary microenvironment play...

    Authors: Pei Yu, Yubao Han, Lulu Meng, Zengying Tang, Zhiwei Jin, Zhenzhen Zhang, Yunjiang Zhou, Jun Luo, Jianguang Luo, Chao Han, Chao Zhang and Lingyi Kong
    Citation: Molecular Cancer 2024 23:82
  29. The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis t...

    Authors: Congren Wang, Yingying Li, Jinyuan Huang, Huimeng Yan and Bin Zhao
    Citation: Molecular Cancer 2024 23:81
  30. Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types,...

    Authors: Yutao Li, Amit Sharma and Ingo G.H. Schmidt-Wolf
    Citation: Molecular Cancer 2024 23:80
  31. R-loops are prevalent three-stranded nucleic acid structures, comprising a DNA-RNA hybrid and a displaced single-stranded DNA, that frequently form during transcription and may be attributed to genomic stabili...

    Authors: Yufan Ying, Yuqing Wu, Fenghao Zhang, Yijie Tang, Jiahe Yi, Xueyou Ma, Jiangfeng Li, Danni Chen, Xiao Wang, Xiaoyan Liu, Ben Liu, Jindan Luo, Xiangyi Zheng and Liping Xie
    Citation: Molecular Cancer 2024 23:79
  32. The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on...

    Authors: Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona…
    Citation: Molecular Cancer 2024 23:78
  33. Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically rec...

    Authors: Linyan Cheng, Lujun Chen, Yuan Shi, Weiying Gu, Weidong Ding, Xiao Zheng, Yan Liu, Jingting Jiang and Zhuojun Zheng
    Citation: Molecular Cancer 2024 23:77
  34. Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function similarly to secondary lymphoid organs (SLOs). While TLS is generally associated with an anti-tumour immune response i...

    Authors: Yuyuan Zhang, Mengjun Xu, Yuqing Ren, Yuhao Ba, Shutong Liu, Anning Zuo, Hui Xu, Siyuan Weng, Xinwei Han and Zaoqu Liu
    Citation: Molecular Cancer 2024 23:75
  35. Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance. The aim of this study w...

    Authors: Yau-Tuen Chan, Junyu Wu, Yuanjun Lu, Qiucheng Li, Zixin Feng, Lin Xu, Hongchao Yuan, Tingyuan Xing, Cheng Zhang, Hor-Yue Tan, Yibin Feng and Ning Wang
    Citation: Molecular Cancer 2024 23:74
  36. For decades, great strides have been made in the field of immunometabolism. A plethora of evidence ranging from basic mechanisms to clinical transformation has gradually embarked on immunometabolism to the cen...

    Authors: Qin Dang, Borui Li, Bing Jin, Zeng Ye, Xin Lou, Ting Wang, Yan Wang, Xuan Pan, Qiangsheng Hu, Zheng Li, Shunrong Ji, Chenjie Zhou, Xianjun Yu, Yi Qin and Xiaowu Xu
    Citation: Molecular Cancer 2024 23:72
  37. It is generally recognized that tumor cells proliferate more rapidly than normal cells. Due to such an abnormally rapid proliferation rate, cancer cells constantly encounter the limits of insufficient oxygen an...

    Authors: Shichao Yang, Caden Hu, Xiaomei Chen, Yi Tang, Juanjuan Li, Hanqing Yang, Yi Yang, Binwu Ying, Xue Xiao, Shang‑Ze Li, Li Gu and Yahui Zhu
    Citation: Molecular Cancer 2024 23:71
  38. Cellular senescence frequently occurs during anti-cancer treatment, and persistent senescent tumor cells (STCs) unfavorably promote tumor progression through paracrine secretion of the senescence-associated se...

    Authors: Dan Zhang, Jian-Wei Zhang, Hui Xu, Xin Chen, Yu Gao, Huan-Gang Jiang, You Wang, Han Wu, Lei Yang, Wen-Bo Wang, Jing Dai, Ling Xia, Jin Peng and Fu-Xiang Zhou
    Citation: Molecular Cancer 2024 23:70
  39. Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in...

    Authors: Alessandra Zingoni, Fabrizio Antonangeli, Silvano Sozzani, Angela Santoni, Marco Cippitelli and Alessandra Soriani
    Citation: Molecular Cancer 2024 23:68
  40. Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges...

    Authors: Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang and Dongling Zou
    Citation: Molecular Cancer 2024 23:66
  41. Abnormal angiogenesis is crucial for gallbladder cancer (GBC) tumor growth and invasion, highlighting the importance of elucidating the mechanisms underlying this process. LncRNA (long non-coding RNA) is widel...

    Authors: Zhiqiang He, Yuhan Zhong, Parbatraj Regmi, Tianrun Lv, Wenjie Ma, Junke Wang, Fei Liu, Siqi Yang, Yanjie Zhong, Rongxing Zhou, Yanwen Jin, Nansheng Cheng, Yujun Shi, Haijie Hu and Fuyu Li
    Citation: Molecular Cancer 2024 23:65
  42. Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rech...

    Authors: Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam and Vivek Subbiah
    Citation: Molecular Cancer 2024 23:64
  43. Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of single nucleotide polymorphisms (SNPs...

    Authors: Giovanna Polcaro, Luigi Liguori, Valentina Manzo, Annalisa Chianese, Giuliana Donadio, Alessandro Caputo, Giosuè Scognamiglio, Federica Dell’Annunziata, Maddalena Langella, Graziamaria Corbi, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Margot De Marco, Jessica Dal Col, Giovanni Nassa…
    Citation: Molecular Cancer 2024 23:63
  44. While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The...

    Authors: Kaifeng Liu, Meijia Li, Yudong Li, Yutong Li, Zixin Chen, Yiqi Tang, Meitian Yang, Guoquan Deng and Hongwei Liu
    Citation: Molecular Cancer 2024 23:62

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions